|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
doi: 10.1242/10.1242/jcs.00609
Cell Science at a Glance |
School of Animal and Microbial Sciences, University of Reading, Whiteknights, PO Box 228, Reading RG6 6AJ, UK
* Author for correspondence (e-mail: m.j.fry{at}reading.ac.uk)
| Introduction |
|---|
|
|
|---|
|
Although the majority of published studies have focused on the classical
p110-p85 (now known as class I) PI 3-kinases, it has emerged over the past 10
years that the PI 3-kinase superfamily (EC 2.7.1.137) is made up of a large
family of structurally related enzymes, with differing PI substrate
requirements and modes of regulation, which probably accounts for the reported
diversity of function (Rameh and Cantley,
1999
; Fry, 2001
;
Katso et al., 2001
). PCR
cloning strategies and data mining of genome sequencing projects would seem to
set the family limit at eight distinct PI 3-kinase catalytic subunits that are
capable of phosphorylating inositol lipids. These eight isoforms have been
divided into three functional classes on the basis of their protein domain
structure, lipid substrate specificity and associated regulatory subunits:
namely, the class I enzymes, p110
, p110ß, p110
and
p110
; the class II enzymes, PI3K-C2
, PI3K-C2ß and
PI3K-C2
; and the sole class III enzyme, Vps34
(Fry, 2001
;
Katso et al., 2001
).
The relationships between the kinase domains of the different enzymes
identified in the human, fly, worm and yeast genomes are indicated in the
poster by the non-rooted phylogenetic tree, which was prepared using ClustalX
(hs, Homo sapien; dm, Drosophila melanogaster; ce,
Caenorhabditis elegans; sp, Schizosaccharomyces pombe; sc,
Saccharomyces cerivisiae). Simple eukaryotes, such as yeasts, and all
plant species investigated to date seem to possess only a single class III PI
3-kinase. Multicellular invertebrate organisms, exemplified by C.
elegans and D. melanogaster, have a single representative member
of each of the three functional classes. Vertebrate genomes (human, mouse)
contain eight distinct PI 3-kinase genes, with some of the family members
being widely or ubiquitously expressed (e.g. p110
, p110ß,
PI3K-C2
, PI3K-C2ß and Vps34), while others are more restricted to
specific cell and tissue types (e.g. p110
, p110
and
PI3K-C2
). To add to this complexity there is a class IV group of
PI-3-kinase-related protein serine/threonine kinases found in all eukaryotes
(Kastan and Lim, 2000
).
Mammals have four such protein kinases: TOR (the target of the drug
rapamycin), ATM (Ataxia telangiectasia mutated), ATR (Ataxia telangiectasia
mutated related) and DNA-PK (DNA-dependent protein kinase). Here, we focus
solely on the three classes of true PI 3-kinase.
The various 3-phosphorylated lipid products that are produced by these
enzymes [PtdIns(3)P, PtdIns(3,4)P2,
PtdIns(3,5)P2 and PtdIns(3,4,5)P3]
function as part of the mechanism by which a diverse set of signalling
molecules, containing pleckstrin homology (PH), FYVE, Phox (PX) and other
lipid-binding domains, are recruited to various cellular membranes
(Rameh and Cantley, 1999
;
Wurmser et al., 1999
;
Ellson et al., 2002
). Cellular
PI 3-kinase activities are balanced by phosphoinositide 3-phosphatase
activities, found in the tumour suppressor protein PTEN and in members of the
myotubularin (MTM) family (Maehama et al.,
2001
).
| Functional analysis of PI 3-kinases |
|---|
|
|
|---|
, and class III PI 3-kinase activity with an IC50 in
the 1-10 nM range, while it inhibits the class II PI3K-C2
isoform with
an approximate IC50 of 400 nM, and class IV PI-3-kinase-related
enzymes in the 100-300 nM range (data summarising many sources). Similarly,
LY294002 inhibits all PI 3-kinases with an IC50 in the 1-50 µM
range. Thus, at low concentrations, these two inhibitors (preferably used in
parallel) can implicate a PI 3-kinase activity in a cellular process of
interest, but are not suitable for dissecting the involvement of individual PI
3-kinase species. Many pharmaceutical companies are working on
isoform-specific PI 3-kinase inhibitors and it is hoped that in time these
will become available to the research community. Currently alternative
approaches, such as the use of dominant negative mutants, knockout mice or RNA
interference, are necessary to attribute a function to a specific PI 3-kinase
class or isoform unambiguously. | Class I PI 3-kinases |
|---|
|
|
|---|
, p110ß,
p110
and p110
). All class I enzymes share the majority of their
structural features and a common substrate specificity
(Rameh and Cantley, 1999| Class IA |
|---|
|
|
|---|
(human gene
designation PIK3CA all subsequent gene names and chromosomal locations
listed refer to humans), which maps to chromosome 3 at 3q26.3; p110ß
(PIK3CB at 3q23); and p110
(PIK3CD at 1p36.2). All of these PI
3-kinases physically interact with a family of Src homology 2
(SH2)-domain-containing regulatory adaptor proteins. Three distinct genes
encode the p85
(PIK3R1 at 5q12-q13), p85ß (PIK3R2 at 19q13.2q13.4)
and p55
(PIK3R3 at 1p34.1) adaptors, each with a number of possible
splice variants. All members of this `p85' family of adaptors bind to the
N-terminal 100 amino acids (shown in purple) of the class IA PI 3-kinases and
mediate their activation by growth factor receptors (mainly of the
protein-tyrosine kinase family) through the two SH2 domains that bind to
sequence-specific phosphorylated tyrosine residues either on
autophosphorylated receptors or on substrate adaptor proteins. Some of the
p85
and p85ß splice forms also possess an SH3 domain, which can
bind to proline-rich ligands in other proteins instead of, or in addition to,
SH2-domain-mediated recruitment (Fry,
1994
isoform has been shown to regulate the size of the adult heart
(Crackower et al., 2002
and p110ß genes result in embryonic
lethality, pointing to their essential nature. Reports suggest that
p110
may play a role in cell survival, whereas p110ß may be more
important in promoting cell proliferation
(Benistant et al., 2000
in numerous cancers continues to mount
(Fry, 2001
would seem to suggest
that this isoform is critical for full B- and T-cell antigen receptor
signalling (Okkenhaug et al.,
2002| Class IB |
|---|
|
|
|---|
(PIK3CG at 7q21.11) catalytic subunit is the sole class IB
member and differs from the class IA enzymes in its extreme N-terminus
(lacking a p85 binding site) and in its adaptor partner, p101 (PI 3-kinase
regulatory subunit gene, at 17p13.1), which lacks domains found in any other
proteins. Whereas class IA enzymes are preferentially activated by
tyrosine-kinase-mediated signals, the class IB enzyme is linked to
G-protein-coupled receptor (GPCR) systems. Activation of class IB seems to
predominantly involve interactions with Gß
subunits and also
possibly G
subunits (Katso et al.,
2001
plays a key role as a modulator of inflammation and allergy
(Wymann et al., 2003| PI 3-kinase core structure |
|---|
|
|
|---|
, alone and in complex with Ras or PI 3-kinase
inhibitors, have been determined. This provides a basis for understanding this
family of kinases at a molecular level
(Walker et al., 1999| Class II PI 3-kinases |
|---|
|
|
|---|
(PIK3C2A at 11p15.5-p14), PI3K-C2ß (PIK3C2B at 1q32) and PI3K-C2
(PIK3C2G at 12p12). Whereas class I PI 3-kinases reside mainly in the
cytoplasm until recruited to active signalling complexes, the class II PI
3-kinases are largely constitutively associated with membrane structures,
including plasma membrane, intracellular membranes and somewhat surprisingly
with nuclei (Fry, 2001| Class III PI 3-kinases |
|---|
|
|
|---|
This is an exciting time in PI 3-kinase research with various members of this family being linked to key cellular processes and to many human diseases. The major players are now all known and what remains is for us to tease out the individual functions of the isoforms.
| References |
|---|
|
|
|---|
Benistant, C., Chapuis, H. and Roche, S. (2000). A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma. Oncogene 19,5083 -5090.[CrossRef][Medline]
Brown, R. A. and Shepherd, P. R. (2001). Growth factor regulation of the novel class II phosphoinositide 3-kinases. Biochem. Soc. Trans. 29,535 -537.[CrossRef][Medline]
Burda, P., Padilla, S. M., Sarkar, S., and Emr, S. D.
(2002). Retromer function in endosome-to-golgi retrograde
transport is regulated by the yeast Vps34 PtdIns 3-kinase. J. Cell
Sci. 115,3889
-3900.
Crackower, M. A., Oudit, G. Y., Kozieradzki, I., Sarao, R., Sun, H., Sasaki, T., Hirsch, E., Suzuki, A., Shioi, T., Irie-Sasaki, J. et al. (2002). Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signalling pathways. Cell 110,737 -749.[CrossRef][Medline]
Djordjevic, S. and Driscoll, P. C. (2002). Structural insights into substrate specificity and regulatory mechanisms of phosphoinositide 3-kinases. Trends Biol. Sci. 27,426 -432.
Ellson, C. D., Andrews, S., Stephens, L. R. and Hawkins, P.
T. (2002). The PX domain: a new phosphoinositide binding
module. J. Cell Sci.
115,1099
-1105.
Fry, M. J. (1994). Structure, regulation and function of phosphoinositide 3-kinases. Biochem. Biophys. Acta 1226,237 -268.[Medline]
Fry, M. J. (2001). Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play? Breast Cancer Res. 3,304 -312.[CrossRef][Medline]
Futter, C. E., Collinson, L. M., Backer, J. M. and Hopkins, C.
R. (2001) Human VPS34 is required for internal vesicle
formation within multivesicular endosomes. J. Cell
Biol. 155,1251
-1264.
Kastan, M. B. and Lim, D. S. (2000). The many substrates and functions of ATM. Nat. Rev. Mol. Cell Biol. 1,179 -186.[CrossRef][Medline]
Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J. and Waterfield, M. D. (2001). Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis and cancer. Annu. Rev. Cell Dev. Biol. 17,615 -675.[CrossRef][Medline]
Kihara, A., Noda, T., Ishihara, N. and Ohsumi, Y.
(2001). Two distinct Vps34 phosphatidylinositol 3-kinase
complexes function in autophagy and carboxypeptidase Y sorting in
Saccharomyces cerevisiae. J. Cell Biol.
152,519
-530.
Maehama, T., Taylor, G. S. and Dixon, J. E. (2001). PTEN and myotubularin: novel phosphoinositide phosphatases. Annu. Rev. Biochem. 70,247 -279.[CrossRef][Medline]
Okkenhaug, K., Bilancio, A., Fargot, G., Priddle, H., Sancho,
S., Peskett, E., Pearce, W., Meek, S. E., Salpekar, A., Waterfield, M. D.,
Smith, A. J. and Vanhaesebroeck, B. (2002). Impaired B and T
cell antigen receptor signalling in p110delta PI 3-kinase mutant mice.
Science 297,1031
-1034.
Rameh, L. E. and Cantley, L. C. (1999). The
role of phosphoinositide 3-kinase lipid products in cell function.J. Biol. Chem. 274,8347
-8350.
Roggo, L., Bernard, V., Kovacs, A. L., Rose, A. M., Savoy, F., Zetka, M., Wymann, M. P. and Muller, F. (2002) Membrane transport in Caenorhabditis elegans: an essential role for VPS34 at the nuclear membrane. EMBO J. 21,1673 -1683.[CrossRef][Medline]
Stein, R. C. and Waterfield, M. D. (2000). PI 3-kinase inhibition: a target for drug development? Mol. Med. Today 6,347 -357.[CrossRef][Medline]
Vieira, O. V., Botelho, R. J., Rameh, L., Brachmann, S. M.,
Matsuo, T., Davidson, H. W., Schreiber, A., Backer, J. M., Cantley, L. C. and
Grinstein, S. (2001). Distinct roles of class I and class III
phosphatidylinositol 3-kinases in phagosome formation and maturation.J. Cell Biol. 155,19
-25.
Walker, E. H., Perisic, O., Ried, C., Stephens, L. and Williams, R. (1999). Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 402,313 -320.[CrossRef][Medline]
Wurmser, A. E., Gary, J. D. and Emr, S. D.
(1999). Phosphoinositide 3-kinases and their FYVE
domain-containing effectors as regulators of vacuolar/lysosomal membrane
trafficking pathways. J. Biol. Chem.
274,9129
-9132.
Wymann, M. P., Bjorklof, K., Calvez, R., Finan, P., Thomast, M., Trifilieff, A., Barbier, M., Altruda, F., Hirsch, E. and Laffargue, M. (2003) Phosphoinositide 3-kinase gamma: a key modulator in inflammation and allergy. Biochem. Soc. Trans. 31,275 -280.[Medline]
This article has been cited by other articles:
![]() |
H. Xu, Z. Su, J. Wu, M. Yang, J. M. Penninger, C. M. Martin, P. R. Kvietys, and T. Rui The Alarmin Cytokine, High Mobility Group Box 1, Is Produced by Viable Cardiomyocytes and Mediates the Lipopolysaccharide-Induced Myocardial Dysfunction via a TLR4/Phosphatidylinositol 3-Kinase {gamma} Pathway J. Immunol., February 1, 2010; 184(3): 1492 - 1498. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Carrillo-Sepulveda, G. S. Ceravolo, Z. B. Fortes, M. H. Carvalho, R. C. Tostes, F. R. Laurindo, R. C. Webb, and M. L. M. Barreto-Chaves Thyroid hormone stimulates NO production via activation of the PI3K/Akt pathway in vascular myocytes Cardiovasc Res, February 1, 2010; 85(3): 560 - 570. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Srivastava, L. Di, O. Zhdanova, Z. Li, S. Vardhana, Q. Wan, Y. Yan, R. Varma, J. Backer, H. Wulff, et al. The Class II Phosphatidylinositol 3 kinase C2{beta} Is Required for the Activation of the K+ Channel KCa3.1 and CD4 T-Cells Mol. Biol. Cell, September 1, 2009; 20(17): 3783 - 3791. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Balla, Z. Szentpetery, and Y. J. Kim Phosphoinositide Signaling: New Tools and Insights Physiology, August 1, 2009; 24(4): 231 - 244. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Balla Finding Partners for PI3K{gamma}: When 84 Is Better Than 101 Sci. Signal., June 9, 2009; 2(74): pe35 - pe35. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Y. Oudit and J. M. Penninger Cardiac regulation by phosphoinositide 3-kinases and PTEN Cardiovasc Res, May 1, 2009; 82(2): 250 - 260. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Rigor, N. Bodyak, S. Bae, J. H. Choi, L. Zhang, D. Ter-Ovanesyan, Z. He, J. R. McMullen, T. Shioi, S. Izumo, et al. Phosphoinositide 3-kinase Akt signaling pathway interacts with protein kinase C{beta}2 in the regulation of physiologic developmental hypertrophy and heart function Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H566 - H572. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Schoijet, K. Miranda, W. Girard-Dias, W. de Souza, M. M. Flawia, H. N. Torres, R. Docampo, and G. D. Alonso A Trypanosoma cruzi Phosphatidylinositol 3-Kinase (TcVps34) Is Involved in Osmoregulation and Receptor-mediated Endocytosis J. Biol. Chem., November 14, 2008; 283(46): 31541 - 31550. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Bao, L. M. Weiss, V. L. Braunstein, and H. Huang Role of Protein Kinase A in Trypanosoma cruzi Infect. Immun., October 1, 2008; 76(10): 4757 - 4763. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Falasca, W. E. Hughes, V. Dominguez, G. Sala, F. Fostira, M. Q. Fang, R. Cazzolli, P. R. Shepherd, D. E. James, and T. Maffucci The Role of Phosphoinositide 3-Kinase C2{alpha} in Insulin Signaling J. Biol. Chem., September 21, 2007; 282(38): 28226 - 28236. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Caruso-Neves, A. A. S. Pinheiro, H. Cai, J. Souza-Menezes, and W. B. Guggino PKB and megalin determine the survival or death of renal proximal tubule cells PNAS, December 5, 2006; 103(49): 18810 - 18815. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. S. Hall, C. Gabernet-Castello, A. Voak, D. Goulding, S. K. Natesan, and M. C. Field TbVps34, the Trypanosome Orthologue of Vps34, Is Required for Golgi Complex Segregation J. Biol. Chem., September 15, 2006; 281(37): 27600 - 27612. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Sourbier, V. Lindner, H. Lang, A. Agouni, E. Schordan, S. Danilin, S. Rothhut, D. Jacqmin, J.-J. Helwig, and T. Massfelder The Phosphoinositide 3-Kinase/Akt Pathway: A New Target in Human Renal Cell Carcinoma Therapy. Cancer Res., May 15, 2006; 66(10): 5130 - 5142. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wu, K. Zu, M. A. Warren, P. K. Wallace, and C. Ip Delineating the mechanism by which selenium deactivates Akt in prostate cancer cells. Mol. Cancer Ther., February 1, 2006; 5(2): 246 - 252. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Harada, A. B. Truong, T. Cai, and P. A. Khavari The Class II Phosphoinositide 3-Kinase C2{beta} Is Not Essential for Epidermal Differentiation Mol. Cell. Biol., December 15, 2005; 25(24): 11122 - 11130. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Fayard, L. A. Tintignac, A. Baudry, and B. A. Hemmings Protein kinase B/Akt at a glance J. Cell Sci., December 15, 2005; 118(24): 5675 - 5678. [Full Text] [PDF] |
||||
![]() |
C. Caruso-Neves, S.-H. Kwon, and W. B. Guggino Albumin endocytosis in proximal tubule cells is modulated by angiotensin II through an AT2 receptor-mediated protein kinase B activation PNAS, November 29, 2005; 102(48): 17513 - 17518. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Malaiyandi, A. S. Honick, G. L. Rintoul, Q. J. Wang, and I. J. Reynolds Zn2+ Inhibits Mitochondrial Movement in Neurons by Phosphatidylinositol 3-Kinase Activation J. Neurosci., October 12, 2005; 25(41): 9507 - 9514. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Calautti, J. Li, S. Saoncella, J. L. Brissette, and P. F. Goetinck Phosphoinositide 3-Kinase Signaling to Akt Promotes Keratinocyte Differentiation Versus Death J. Biol. Chem., September 23, 2005; 280(38): 32856 - 32865. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Maffucci, E. Piccolo, A. Cumashi, M. Iezzi, A. M. Riley, A. Saiardi, H. Y. Godage, C. Rossi, M. Broggini, S. Iacobelli, et al. Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway by Inositol Pentakisphosphate Results in Antiangiogenic and Antitumor Effects Cancer Res., September 15, 2005; 65(18): 8339 - 8349. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Y. Siu, C.-h. Wong, W. M. Lee, and C. Y. Cheng Sertoli-Germ Cell Anchoring Junction Dynamics in the Testis Are Regulated by an Interplay of Lipid and Protein Kinases J. Biol. Chem., July 1, 2005; 280(26): 25029 - 25047. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Maffucci, F. T. Cooke, F. M. Foster, C. J. Traer, M. J. Fry, and M. Falasca Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration J. Cell Biol., June 6, 2005; 169(5): 789 - 799. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Budzyn, P. D. Marley, and C. G. Sobey Opposing Roles of Endothelial and Smooth Muscle Phosphatidylinositol 3-Kinase in Vasoconstriction: Effects of Rho-Kinase and Hypertension J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1248 - 1253. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nunomura, Y. Gon, T. Yoshimaru, Y. Suzuki, H. Nishimoto, T. Kawakami, and C. Ra Role of the Fc{epsilon}RI {beta}-chain ITAM as a signal regulator for mast cell activation with monomeric IgE Int. Immunol., June 1, 2005; 17(6): 685 - 694. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Kinlough, P. A. Poland, J. B. Bruns, K. L. Harkleroad, and R. P. Hughey MUC1 Membrane Trafficking Is Modulated by Multiple Interactions J. Biol. Chem., December 17, 2004; 279(51): 53071 - 53077. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Gibbins Platelet adhesion signalling and the regulation of thrombus formation J. Cell Sci., July 15, 2004; 117(16): 3415 - 3425. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Sheu, F. M. Ho, K. F. Chao, M. L. Kuo, and S. H. Liu Activation of Phosphoinositide 3-kinase in Response to High Glucose Leads to Regulation of Reactive Oxygen Species-Related Nuclear Factor-{kappa}B Activation and Cyclooxygenase-2 Expression in Mesangial Cells Mol. Pharmacol., July 1, 2004; 66(1): 187 - 196. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Rawlings, K. M. Rosler, and D. A. Harrison The JAK/STAT signaling pathway J. Cell Sci., March 15, 2004; 117(8): 1281 - 1283. [Full Text] [PDF] |
||||
![]() |
S. Merlot and R. A. Firtel Leading the way: directional sensing through phosphatidylinositol 3-kinase and other signaling pathways J. Cell Sci., September 1, 2003; 116(17): 3471 - 3478. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||